Brief: Ose Immunotherapeutics, Veloxis Sign Global License Agreement On FR104
26/04/2021 17:02
April 26 (Reuters) - Ose Immunotherapeutics SA OSE.PA :
* OSE IMMUNOTHERAPEUTICS AND VELOXIS PHARMACEUTICALS ENTER
INTO
GLOBAL LICENSE AGREEMENT TO DEVELOP, MANUFACTURE, AND
COMMERCIALIZE FR104, A CD28 ANTAGONIST, IN THE ORGAN
TRANSPLANTATION MARKET
* ACCORDING TO AGREEMENT, OSE IMMUNOTHERAPEUTICS WILL
RECEIVE UP
TO EUR 315 MILLION IN POTENTIAL MILESTONES FROM VELOXIS
* VELOXIS WILL ASSUME ALL PRODUCTION, DEVELOPMENT AND
COMMERCIALIZATION COSTS IN TRANSPLANT INDICATIONS FOR FR104
Source text for Eikon: ID:nBw9prpKma
Further company coverage: OSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO